As we have informed here, the AMR Action Fund, the world’s largest public-private partnership investing in biotech companies that are developing antimicrobials, has invested in BioVersys, a clinical-stage company based in Basel, Switzerland.
The transaction marks the Fund’s first investment in Europe and is an important step toward building an international portfolio of companies that are de-veloping urgently needed antimicrobials. BioVersys is focusing on research and develop-ment of therapies for life-threatening multidrug-resistant bacterial infections and targeted mi-crobiome modulation. With this investment, BioVersys extended its Series C investment round to CHF 32.6m.
VISCHER has advised AMR Action Fund with a team lead by partner Matthias Staehelin (pictured) with Sebastian Flückiger, Balthasar Müller and Natacha Tang (all corporate/m&a).